Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-4849 combination therapy in malignant solid tumors (Phase II, multicenter, open-label)
ChiCTR2600117863Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of SHR-4849 in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC), neuroendocrine carcinoma (NEC) and 1 more (8 arms), sponsored by Shandong Cancer Hospital. Primary endpoints: Incidence of dose-limiting toxicity (DLT) and Incidence and severity of adverse events (AE) and serious adverse events (SAE). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
SHR-4849
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)neuroendocrine carcinoma (NEC)Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2600117863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117863.